CRBN and Miyoshi myopathy: Among the emerging therapies in this setting are the new, investigational, orally administered cereblon E3 ligase modulators (CELMoDs) iberdomide and mezigdomide, both of which have orphan drug designation status (codes 665718 and 685019) with the United States Food and Drug Administration for the treatment of MM but are not yet approved in this setting.